α1-Blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: What are the relevant differences in randomised controlled trials?

European Urology

Volumn 38, Issue SUPPL. 1, 2000, Pages 25-39

  De Mey, Christian ^a,b  

^a ACPS   (Germany)

^b ACPS Applied Clinical Pharmacology Services   (Germany)

Author keywords

Alfuzosin; Alpha blockers; Doxazosin; Lower urinary tract symptoms; Randomised controlled trials; Tamsulosin; Terazosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MICTURITION; PRIORITY JOURNAL; PROSTATE DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; URINARY TRACT DISEASE; VERTIGO; COMPARATIVE STUDY; MALE; PROSTATE HYPERTROPHY; REVIEW; URETHRA OBSTRUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; URETHRAL OBSTRUCTION;

EID: 0033667530     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052399     Document Type: Conference Paper

References (166)

1. The architecture of clinical research
2. Usefulness, usability and quality criteria for noninvasive methods in cardiovascular clinical pharmacology
3. Patient Information and consent in trials for the treatment of benign prostatic obstruction
4. The design and analysis of randomized controlled trials of treatments for lower urinary tract symptoms
5. Unbiased and reliable estimates in health care
6. Quality assurance operations: Good clinical practices
7. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community
8. Randomized controlled trials for benign prostatic obstruction: Problems and pitfalls
9. The International Conference on Harmonization Good Clinical Practice guideline
10. Review of ethics curricula in undergraduate medical education
11. Clinical pharmacology and therapeutics in a changing world
12. Report from the American Board of Clinical Pharmacology
13. Reports of randomized trials in acute stroke, 1955 to 1995. What proportions were commercially sponsored?
14. The Prostate Trials Office reasearch protocols
15. Methodological and political issues in clinical pharmacology research by the year 2000
16. Clinical trials and tribulations: A personal view of interacting with pharmaceutical manufacturers
17. The procedure of new drug application and the philosophy of critical rationalism or the limits of quality assurance with good clinical practice
18. Who should be treated and how? Evidence-based medicine in symptomatic BPH
19. Evaluation of benign prostatic hyperplasia treatments: How can we improve the outcome measures and success criteria?
20. Obstructive benign prostatic hyperplasia: Therapeutical aspects
21. Benign prostatic hyperplasia: Use of drug therapy in primary care
22. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia
23. Current management options for benign prostatic hyperplasia
24. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia
25. World Health Organization Consensus Committee recommendations concerning the diagnosis of BPH
26. International consultation on benign prostatic hyperplasia
27. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States
28. Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH)
29. And now, evidence based editing
30. Publication bias: The case for an international registry of clinical trials
31. Source of funding and outcome of clinical trials
32. Publication bias: Evidence of delayed publication in a cohort study of clinical research projects
33. Reference bias in reports of drug trials
34. Impact of prostate size on response to medical therapy for benign prostatic hyperplasia (BPH): Results of the PREDICT trial
35. Relationship between age, lower urinary tract symptoms (LUTS) and various domains of erectile dysfunction in 1,098 patients with BPH in the PREDICT study
36. Completeness of reporting of trials published in languages other than English: Implications for conduct and reporting of systematic reviews
37. Authors' criteria for selecting journals
38. Preparing reports of randomized controlled trials. The Checklist
39. A proposal for structured reporting of randomized controlled trials
40. Better reporting of randomized controlled trials: The CONSORT statement
41. The measurement of symptoms, quality of life and sexual function
42. Symptom indices in bladder outlet obstruction
43. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes
44. The symptom questionnaire for benign prostatic hyperplasia: An ambiguous indicator for an ambiguous disease
45. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?
46. A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic diseases using transrectal sonography
47. Significant correlation of the American Urological Association symptom score and a novel urodynamic parameter: Detrusor contraction duration
48. Does anamnestic symptom evaluation or clinical examination give enough information to evaluate the severity of obstruction in benign prostatic hyperplasia?
49. Benign prostatic hyperplasia in an unselected community-based population: A survey of urinary symptoms, bothersomeness and prostatic enlargement
50. Comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia
51. Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia
52. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
53. Benign prostatic hyperplasia: Diagnosis and treatment. AHCPR. Agency for Health Care Policy and Research
54. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
55. 1-adrenoceptor subtype-specific blockade
56. Treatment of benign prostatic hyperplasia with alpha1-adrenoceptor antagonists
57. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia
58. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group
59. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study
60. Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up
61. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy
62. 1-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH)
63. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group
64. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study
65. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study
66. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia
67. Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies
68. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: The Hypertension and BPH Intervention Trial (HABIT)
69. The effect of age in the usage of alpha receptor blocker treatment in prostate patients
70. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
71. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
72. Christofis: Influence of prostate size on terazosin efficacy
73. Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging
74. Use of meta-analytic results to facilitate shared decision making
75. Tamsulosin, the first prostate-selective α(1A)-adrenoceptor antagonist: A meta-analysis of two randomized, placebo-controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH)
76. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia
77. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia
78. Long term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial
79. Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia
80. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: Results from three double-blind placebo-controlled studies
81. Tamsulosin for the treatment of benign prostatic hypertrophy
82. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension
83. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years
84. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12-18 month assessment. BPHALF Group
85. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group
86. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia
87. Doxazosin: A new approach to hypertension and benign prostatic hyperplasia
88. Terazosin: A new alpha adrenoceptor blocking drug
89. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
90. The role of alpha 1-blockers in combination therapy for hypertension
91. Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia
92. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies
93. Doxazosin for benign prostatic hyperplasia in primary care
94. Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men
95. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications
96. Terazosin in benign prostatic hyperplasia: Effects on blood pressure in normotensive and hypertensive men
97. The international terazosin trial: A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group
98. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis
99. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia
100. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction
101. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the nanagement of symptomatic benign prostatic hyperplasia
102. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)
103. Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group
104. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: Interactions with anti-hypertensive therapy
105. Hypertension in the elderly with coexisting benign prostatic hyperplasia
106. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
107. Clinical uroselectivity of alfuzosin in the treatment benign prostatic hyperplasia
108. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists
109. Comparison of the new alpha-1 blocker alfuzosin with propranolol as first-line therapy in hypertension
110. Dose titration study of alfuzosin, a new alpha1-adrenoceptor blocker, in essential hypertension
111. Alfuzosin and the venous reflex response: Studies in normal subjects
112. Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man
113. Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses
114. Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin
115. Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction
116. Clinical experience with alfuzosin in benign prostatic hyperplasia
117. Adverse effects of alpha 1-adrenergic blocking drugs
118. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: Impact on safety and well-being
119. Alpha1-blockers for BPH: Are there differences?
120. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia
121. Tamsulosin: 3-year long efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: Analysis of a European, multinational, multicenter, open-label study
122. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group
123. Sexual function in men with BPH treated with either an alpha adrenergic blocker, alfuzosin or the aplha-reductase inhibitor, finasteride, or the combination. A European randomized study in 1,051 patients
124. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
125. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HY-CAT Investigator Group
126. BPH and sexuality
127. Tamsulosin 0.4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
128. Alpha-1 blockade pharmaco-therapy in primitive psychogenic premature ejaculation resistant to psychotherapy
129. A dose titration study evaluating terazosin, a selective, once-a-day alpha1-blocker for the treatment of symptomatic benign prostatic hyperplasia
130. Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study
131. Comparison of relaxation responses of cavernous and trigonal smooth muscles from rabbits by alpha1-adrenoceptor antagonists; prazosin, terazosin, doxazosin, and tamsulosin
132. A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia
133. Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: A pilot study
134. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups
135. Terazosin and doxazosin in normotensive men with symptomatic prostatism: A pilot study to determine the effect of dosing regimen on efficacy and safety
136. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: Pharmacokinetics, efficacy and safety
137. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group
138. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia
139. Pharmacokinetic and metabolic profiles of alfuzosin
140. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia
141. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
142. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension
143. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazo-sin Investigators' Study Group
144. Alpha1-adrenoceptor selectivity: The North American Experience
145. Diuretics vs alpha-blockers for treatment of hypertension: Lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
146. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group
147. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: Interactions with anti-hypertensive therapy
148. Clinical pharmacology of modern antihypertensive agents and their interaction with alpha-adrenoceptor antagonists
149. Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans
150. A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors
151. Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin
152. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review
153. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
154. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
155. Clinical comparison of selective and non-selective alpha 1A-adre-noceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group
156. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: Comparative study with prazosin. The PRAZALF Group
157. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group
158. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short-term, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia
159. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
160. Orthostatic efects of alfuzosin twice daily vs. tamsulosin once daily in the morning. AUA, Atlanta 2000
161. Evidence-based medicine: An approach to clinical problem solving
162. The science of reviewing research
163. Systematic reviews: Synthesis of best evidence for clinical decisions
164. The medical review article: State of the science
165. A review of studies published during 1998 examining the treatment and management of benign prostatic obstruction